Femara (with the generic formula of letrozole) is basically an oral drug that is popularly effective in fertility treatment for women suffering from ovulation problems or unexplained infertility. It belongs to the group of aromatase inhibitors. Femara also has an active role in treating multiple cases of breast cancer. Being superior in form than Clomifen, Letrozole can actively act upon those human female subjects who don’t respond to Clomifen. Unlike Clomifen, Letrozole never imparts unpleasant side-effects if stopped.
Why to use: Femara, as an effective aromatase inhibitor, suppress estrogen levels in young females that consequently increases the FSH (Follicle Stimulating Hormone) output from pituitary gland resulting into development of a mature follicle in the ovary and ovulation of an egg. Thus, in human females suffering from polycystic ovary syndrome or anovulation (problem with normal ovulation), it can induce ovulation or what doctors term as “induction of ovulation. Women, who already ovulates their own, can enjoy the benefits of multiple follicles and multiple eggs releasing while on treatment of Femara. Such phenomenon can promote the chances of pregnancy compared to release of a single egg during natural menstruation cycle. Such phenomenon is termed as superovulation or controlled ovarian hypestimulation in medical terminologies. Again, in cases of intrauterine insemination (IUI), Femara has always played a significant role to improve the chances of pregnancy. It has promoted about 15 % chances of healthy pregnancy in women with ovarian complexities per month that, to some extent, depends on factors like age of the subject, status of the fallopian tube and male’s sperm quality.
Users’ Guidelines: Commonly, Femara is administered as 2.5 mg per day on days five through nine of the menstrual cycle. Sometimes, higher doses of 5 mg or 7.5 mg per day can also used.
Higher incidence of birth defects though it is under controversy